-
公开(公告)号：US12064440B2
公开(公告)日：2024-08-20
申请号：US18187507
申请日：2023-03-21
IPC分类号： A61K31/5575 , A61K9/00 , A61K9/06 , A61K9/08 , A61K31/5377 , A61K47/02 , A61K47/18
CPC分类号： A61K31/5575 , A61K9/0019 , A61K9/0048 , A61K9/06 , A61K9/08 , A61K31/5377 , A61K47/02 , A61K47/186
摘要： The present invention provides pharmaceutically acceptable and ophthalmologically suitable gel compositions comprising a therapeutically effective amount of a bimatoprost compound, a therapeutically effective amount of a timolol compound, and benzalkonium chloride. In certain embodiments, compositions provided by the invention further comprise a penetration enhancer component other than benzalkonium chloride. Further, the invention provides a process of preparing such compositions and methods of their use in treating ocular conditions, such as methods of reducing elevated intraocular pressure and/or treating glaucoma, such as open-angle glaucoma.
-
公开(公告)号：US12016855B2
公开(公告)日：2024-06-25
申请号：US17458533
申请日：2021-08-26
IPC分类号： A61K31/4709 , A61K9/00 , A61K9/08 , A61K31/567 , A61K31/573 , A61K47/18 , A61K47/26 , A61K47/36 , A61K47/44
CPC分类号： A61K31/4709 , A61K9/0048 , A61K9/08 , A61K31/567 , A61K31/573 , A61K47/183 , A61K47/26 , A61K47/36 , A61K47/44
摘要： Provided here are new ophthalmologically suitable pharmaceutical compositions comprising an effective amount of a moxifloxacin compound and an effective amount of a prednisolone compound. In aspects, the compositions are stable suspensions, which maintain physical stability and chemical stability for extended periods of time (e.g., exhibiting no sustained flocculation, coagulation, or clumping after several months of storage under typical storage conditions). In aspects, the compositions are suspensions that include a suspension component comprising one or more suspension agents. In aspects, the suspension component includes an ionic suspension agent. In aspects, the composition also or alternatively comprises a non-ionic surfactant, non-ionic suspension agent, or both, or an agent that provides both functions. In aspects, such compositions further comprise an effective amount of a chelating agent/component. Further described are related compositions and methods of making and using such compositions, e.g., in the treatment of eye infections.
-
公开(公告)号：US20240197676A1
公开(公告)日：2024-06-20
申请号：US18587762
申请日：2024-02-26
IPC分类号： A61K31/375 , A61K47/02 , A61K47/18
CPC分类号： A61K31/375 , A61K47/02 , A61K47/183
摘要： The invention described here provides ready-to-use (RTU) pharmaceutical compositions in single unit dose packaging, such compositions including ascorbic acid compound(s), such as sodium ascorbate, and one or more pharmaceutically acceptable excipients (e.g., a carrier and optionally other agents, such as a tonicity agent, a chelator, or both). The compositions provided by the invention are stable when stored at 20° C. to 25° C.±2° C. for at least about 3 months. Compositions provided by the invention comprise an osmolality of between about 270 mOsm/kg to about 340 mOsm/kg and do not require dilution or further manipulation prior to use. In certain aspects, the invention comprises methods of using such compositions in the treatment of diseases, conditions, or symptoms related to vitamin C deficiency, such as, in specific embodiments, scurvy.
-
公开(公告)号：US11969410B2
公开(公告)日：2024-04-30
申请号：US18167057
申请日：2023-02-09
IPC分类号： A61K31/4178 , A61K9/00 , A61K9/08 , A61K31/14 , A61K31/498 , A61K47/02 , A61K47/18 , A61K47/26 , A61K47/44
CPC分类号： A61K31/4178 , A61K9/0048 , A61K9/08 , A61K31/14 , A61K31/498 , A61K47/02 , A61K47/186 , A61K47/26 , A61K47/44
摘要： The present invention provides relatively low pH, stable, pharmaceutically acceptable and ophthalmologically suitable compositions comprising effective amounts of pilocarpine and brimonidine compounds for treating an ocular condition, wherein compositions demonstrate a significant difference in the amount or rate of one or more pharmaceutical ingredient(s) absorbed or retained by ocular tissue or compared to reference composition(s) with similar compositional characteristics but having a significantly higher pH. In aspects compositions are characterizable by other elements, e.g., the inclusion of benzalkonium chloride, a limited amount of sodium chloride, or both. In embodiments, compositions are free of both a borate and a citrate buffer. Compositions provided by the invention surprisingly demonstrate pharmaceutically acceptable stability when stored under controlled room temperature conditions for an extended period of time. Further, the invention provides methods of manufacturing such compositions in liquid (solution) and gel forms, and methods of their use in treating conditions such as presbyopia.
-
公开(公告)号：US11786538B2
公开(公告)日：2023-10-17
申请号：US17114936
申请日：2020-12-08
IPC分类号： A61K31/5575 , A61K31/14 , A61K9/08 , A61K47/44 , A61K9/00 , A61K47/26 , A61K31/165 , A61K47/02 , A61K47/12 , A61K47/18
CPC分类号： A61K31/5575 , A61K9/0048 , A61K9/08 , A61K31/14 , A61K31/165 , A61K47/02 , A61K47/12 , A61K47/186 , A61K47/26 , A61K47/44
摘要： The present invention relates to ophthalmic compositions comprising from 0.005% to 0.02% bimatoprost by weight, less than 100 ppm benzalkonium chloride, and a secondary penetration enhancer that detectably enhances penetration of bimatoprost into a mammalian eye such that elevated intraocular pressure is effectively reduced to an extent statistically comparable to compositions comprising higher amounts of bimatoprost and benzalkonium chloride. Further, the invention also provides a process of preparing such compositions and methods of their use for lowering intraocular pressure and treating glaucoma.
-
6.发明公开公开(公告)号：US20230263775A1
公开(公告)日：2023-08-24
申请号：US18154524
申请日：2023-01-13
IPC分类号： A61K31/4178 , A61K9/08 , A61K9/00 , A61K47/18 , A61K47/12 , A61K47/26 , A61K9/06 , A61K47/36
CPC分类号： A61K31/4178 , A61K9/06 , A61K9/08 , A61K9/0048 , A61K47/12 , A61K47/18 , A61K47/26 , A61K47/36 , A61K47/186
摘要： Disclosed herein, are, among other things, stable, pharmaceutically acceptable and ophthalmologically suitable reduced buffer content and reduced buffering capacity pilocarpine compound compositions. In aspects, such compositions comprise therapeutically effective amounts of a pilocarpine compound, an effective amount of a uniform buffer component, wherein the concentrations of pilocarpine compound and uniform buffer component are limited to specific relative amounts and wherein the uniform buffer component is defined by one or more markedly distinguishing characteristics from buffers used in developed pilocarpine products (e.g., a unique pKa and/or concentration). Aspects of the invention include compositions defined by unique concentrations of such and other ingredients. Such compositions surprisingly exhibit pharmaceutically acceptable stability and, in aspects, stability equal to or statistically significantly greater than that of one or more on-market/developed reference product(s). Further, the invention provides methods of manufacturing such and similar compositions, and methods of their use in treating ocular conditions such as presbyopia.
-
7.发明公开公开(公告)号：US20230181526A1
公开(公告)日：2023-06-15
申请号：US18064222
申请日：2022-12-09
IPC分类号： A61K31/375 , A61K9/00 , A61K47/02 , A61K47/26
CPC分类号： A61K31/375 , A61K9/0019 , A61K47/02 , A61K47/26
摘要： The invention described here provides methods of efficiently treating vitamin C deficiency-related diseases and other conditions comprising the administration of pharmaceutical compositions comprising ascorbic acid compound(s), such as sodium ascorbate, and one or more pharmaceutically acceptable excipients (e.g., a carrier and optionally other agents, such as a tonicity agent, a chelator, or both). The methods comprise administration of such compositions in ready-to-use (RTU) form, provided in single unit dose packaging, wherein the compositions are stable when stored at 20° C. to 25° C. ± 2° C. for at least about 3 months. Compositions provided by the invention comprise an osmolality of between about 270 mOsm/kg to about 340 mOsm/kg and do not require dilution or further manipulation prior to use.
-
8.发明授权公开(公告)号：US11471403B2
公开(公告)日：2022-10-18
申请号：US17686371
申请日：2022-03-03
IPC分类号： A61K9/00 , A61K31/4709 , A61K31/519 , A61K47/26 , A61P31/04 , A61K47/38 , A61K47/18 , A61P27/02 , A61K47/36
摘要： Provided here are new ophthalmologically suitable pharmaceutical compositions comprising an effective amount of a moxifloxacin compound and an effective amount of a triamcinolone compound in suspension, wherein the particles of the suspension are limited in size. In aspects, the compositions are stable suspensions, maintaining physical stability and chemical stability for extended periods of time (e.g., exhibiting no sustained flocculation, coagulation, or clumping after several months of storage under typical storage conditions). In aspects, the compositions include a suspension component comprising one or more suspension agents. In aspects, the suspension component includes an ionic suspension agent. In aspects, the composition also or alternatively comprises a non-ionic surfactant, non-ionic suspension agent, or both, or an agent providing both functions. In aspects, such compositions further comprise an effective amount of a chelating agent/component. Further described are related compositions and methods of making and using such compositions, e.g., in the treatment of eye infections.
-
公开(公告)号：US11439591B2
公开(公告)日：2022-09-13
申请号：US17686368
申请日：2022-03-03
IPC分类号： A61K9/00 , A61K31/519 , A61K47/26 , A61K47/38 , A61K47/18 , A61K47/36 , A61K31/4709 , A61P31/04 , A61P27/02 , A61K31/04
摘要： Provided here are new ophthalmologically suitable pharmaceutical compositions comprising an effective amount of a moxifloxacin compound and an effective amount of a triamcinolone compound. In aspects, the compositions are stable suspensions, which maintain physical stability and chemical stability for extended periods of time (e.g., exhibiting no sustained flocculation, coagulation, or clumping after several months of storage under typical storage conditions). In aspects, the compositions are suspensions that include a suspension component comprising one or more suspension agents. In aspects, the suspension component includes an ionic suspension agent. In aspects, the composition also or alternatively comprises a non-ionic surfactant, non-ionic suspension agent, or both, or an agent that provides both functions. Further described are related compositions and methods of making and using such compositions, e.g., in the treatment of eye infections.
-
10.发明申请公开(公告)号：US20220183967A1
公开(公告)日：2022-06-16
申请号：US17686371
申请日：2022-03-03
IPC分类号： A61K9/00 , A61K31/4709 , A61K31/519 , A61K47/26 , A61P31/04 , A61K47/38 , A61K47/18 , A61P27/02 , A61K47/36
摘要： Provided here are new ophthalmologically suitable pharmaceutical compositions comprising an effective amount of a moxifloxacin compound and an effective amount of a triamcinolone compound in suspension, wherein the particles of the suspension are limited in size. In aspects, the compositions are stable suspensions, maintaining physical stability and chemical stability for extended periods of time (e.g., exhibiting no sustained flocculation, coagulation, or clumping after several months of storage under typical storage conditions). In aspects, the compositions include a suspension component comprising one or more suspension agents. In aspects, the suspension component includes an ionic suspension agent. In aspects, the composition also or alternatively comprises a non-ionic surfactant, non-ionic suspension agent, or both, or an agent providing both functions. In aspects, such compositions further comprise an effective amount of a chelating agent/component. Further described are related compositions and methods of making and using such compositions, e.g., in the treatment of eye infections.
-
-
-
-
-
-
-
-
-
搜索结果
89 条记录 (耗时 0.035 秒)
